Key Takeaways
- Isomorphic Labs, a spinout of Google DeepMind, prepares to initiate human trials for its first AI-designed drug candidates
- Backed by $600M in funding and partnerships with Novartis and Eli Lilly, the company aims to radically reduce timelines and improve trial success rates
- Inspired by AlphaFold’s Nobel-winning protein folding AI, the company brings a new era of precision drug discovery into the clinic
AI to Clinic: Isomorphic Labs Moves Beyond Design to Human Trials
Isomorphic Labs, the AI drug discovery venture born from Google DeepMind, is entering a pivotal stage: the launch of human clinical trials for drugs developed using generative AI. The company has confirmed it’s staffing up and preparing trial logistics for candidates aimed at treating oncology and immunology conditions. This milestone marks a shift from algorithmic prediction to in-human validation of AI-designed therapies, turning a high-potential concept into clinical reality.
$600M in Funding and Big Pharma Collaborations Fuel Pipeline Expansion
To support its ambitious goals, Isomorphic Labs secured $600 million in fresh capital in April 2025. Strategic partnerships with pharma giants such as Novartis and Eli Lilly enable the company to co-develop drugs with real-world impact. This investment underscores market confidence in AI-first drug R&D platforms and positions Isomorphic as one of the best-funded biotech ventures leveraging machine learning for translational research.
AlphaFold’s Legacy Inspires Next-Gen Drug Discovery Models
The scientific credibility behind Isomorphic Labs traces back to DeepMind’s AlphaFold—an AI system that revolutionized biology by predicting protein structures with unprecedented accuracy. Its co-creators won the 2024 Nobel Prize in Chemistry, lending weight to the foundational science behind Isomorphic’s platform. By embedding this protein-mapping technology into the early stages of compound development, the lab creates a seamless continuum from target identification to molecular design.
Transforming the Economics and Efficacy of Drug Development
The traditional drug development model is slow, costly, and risky—often requiring over $1B per successful drug and facing a 90% failure rate in trials. Isomorphic Labs aims to disrupt this with an AI-first model that speeds up discovery, cuts costs, and increases success probability by identifying better candidates early. Their long-term vision includes building an end-to-end platform where AI can autonomously propose viable drug designs—bringing the industry closer to click-to-create drug discovery.
About Isomorphic Labs
Founded in 2021 as a sister company to Google DeepMind, Isomorphic Labs uses deep learning and advanced protein modeling to reinvent how medicines are discovered. Drawing on breakthroughs from AlphaFold and other AI tools, the company collaborates with pharmaceutical leaders to develop novel therapies across cancer, immunology, and rare diseases. With AI at its core and translational science as its goal, Isomorphic represents a new paradigm in biotech innovation.
By
